Ticker LaunchUplisting · SBFM
Sunshine Biopharma Inc.
Formerly Sunshine Biopharma, Inc; Mountain West Business Solutions, Inc; mountain west business solutions,inc
Sunshine Biopharma Inc. (SBFM), already reporting to the SEC, moved up to Nasdaq Capital Market on Feb 17, 2022 with an offering at $4.25 per share raising $8M. Aegis Capital was lead-left underwriter. Sichenzia Ross Ference Carmel advised the company and Andrew I. Telsey and Kaufman & Canoles advised the underwriters.
Sunshine Biopharma Inc. is a pharmaceutical and nutritional supplement company based in Pointe-Claire, Quebec, Canada. It researches proprietary drugs, including the anti-cancer compound Adva-27a and the anti-coronavirus candidate SBFM-PL4, and its Canadian subsidiary develops and sells a nutritional supplement.
- Status
- Uplisting
- Ticker
- SBFM
- Exchange
- Nasdaq Capital Market
- Listed
- Feb 17, 2022
- Price
- $4.25
- Raised
- $8M
- Market cap at IPO price
- $19M
- First filed
- May 22, 2014
- Underwriters
- Aegis Capital
- Company counsel
- Sichenzia Ross Ference Carmel
- Underwriters' counsel
- Andrew I. Telsey and Kaufman & Canoles
- Sector
- Biotech & pharma
- Country / state
- FL
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed May 22, 2014
- Latest amendment Feb 14, 2022
- Final prospectus (424B4) Feb 17, 2022
- All filings on EDGAR CIK 1402328
Other Biotech & pharma uplistings in 2022
- Silo Pharma, Inc.SILO · Sep 28, 2022